Analysis Of The Efficacy And Safety Of The Fixed-Dose Combination Of Tiotropium + Olodaterol In Patients With COPD By Previous Usage Of Inhaled Corticosteroids

Rationale: Tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β2-agonist (both administered once-daily), have been studied as a once-daily fixed-dose combination (FDC). Two Phase III studies have demonstrated that T+O FDC significantly improved lung function and symptoms over T and O monotherapy treatments in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).1 During these studies, patients were allowed to continue existing treatment with inhaled corticosteroids (ICS); this analysis was conducted to determine the effects of study treatment on l…